8-K: SCPH Secures $10M Bridge Loan from MannKind

scPharmaceuticals Inc. obtained a $10.0 million unsecured promissory note from MannKind Corporation to support operations during their pending merger.

Summary

• scPharmaceuticals Inc. (SCPH) issued an unsecured promissory note for $10.0 million to MannKind Corporation.
• The loan, dated September 23, 2025, is intended to provide working capital and for general corporate purposes.
• It is connected to the previously disclosed Agreement and Plan of Merger, dated August 24, 2025, where MannKind plans to acquire scPharmaceuticals.
• The note matures on the earliest of September 23, 2026, the date of the merger termination fee payment, or the consummation of a superior proposal.
• Interest accrues at a per annum rate equal to MannKind's SOFR Loans rate under its Credit Agreement, with specific adjustments for Applicable Margin changes (4.75% or 5.00%) or Credit Agreement termination (Adjusted Term SOFR plus 4.75%).
• The initial interest rate is 9.00467%, applicable until November 6, 2025.
• The first interest payment of $110,057.08 is due on November 6, 2025.
• scPharmaceuticals has the option to prepay the loan in full at any time prior to the Maturity Date.
• The note includes customary affirmative and negative covenants, restricting scPharmaceuticals' ability to incur additional indebtedness and liens, with certain baskets increased by 25%.
• Events of default, including failure to pay principal or interest, covenant breaches, or bankruptcy events, could trigger immediate repayment.

Sentiment

Score: 6

Explanation: The filing describes a necessary and expected financing step within the context of a pending merger. It provides liquidity and operational stability, which is positive, but also adds debt and covenants. The overall sentiment is neutral to slightly positive as it facilitates the ongoing business and merger process without introducing significant new risks beyond those inherent in the merger itself.

Positives

• Secured $10.0 million in unsecured financing, providing crucial working capital.
• The loan supports ongoing operations during the pendency of the merger agreement.
• The company retains the option to prepay the loan in full.

Negatives

• Incurring new debt adds to the company's financial obligations.
• Negative covenants restrict the company's ability to incur further indebtedness and liens while the note is outstanding.
• The interest rate is variable and tied to MannKind's borrowing costs, introducing some uncertainty.
• Events of default could lead to accelerated repayment, posing a liquidity risk.

Risks

• **Liquidity Risk:** Failure to meet payment obligations or breach covenants could trigger an event of default, leading to immediate repayment of the $10.0 million principal and accrued interest.
• **Merger Termination Risk:** The note's maturity is tied to the merger agreement's outcome, including potential termination or a superior proposal, which could accelerate or alter repayment terms.
• **Interest Rate Risk:** The interest rate is variable, linked to SOFR and MannKind's Credit Agreement, exposing the company to potential increases in borrowing costs.
• **Covenant Compliance Risk:** Restrictions on incurring additional indebtedness and liens could limit operational flexibility or future financing options if not carefully managed.

Future Outlook

The company intends to use the proceeds from the promissory note for ongoing working capital requirements and other general corporate purposes. The maturity of the loan is contingent on the outcome of the pending merger with MannKind Corporation or the consummation of a potential superior acquisition proposal.

Management Comments

• The company will use the proceeds of this Note to provide for ongoing working capital requirements and for other general corporate purposes.

Industry Context

In the biopharmaceutical industry, companies often require significant capital for research, development, and commercialization. Bridge financing, such as this unsecured promissory note, is a common mechanism to ensure liquidity and operational continuity for target companies during the period between the announcement and closing of an acquisition. This allows the target to maintain operations without disruption while the merger process unfolds, which is crucial for preserving asset value and employee morale.

Comparison to Industry Standards

• This financing arrangement is a standard bridge loan provided by an acquirer to a target company during a pending merger. It is designed to provide immediate liquidity and operational stability.
• Specific comparable companies or projects are not detailed in the filing, but such arrangements are common in M&A transactions, particularly when the target company requires capital to sustain operations until the deal closes.
• The terms, including interest rates tied to the acquirer's cost of capital and covenants, are typical for such inter-company financing within an acquisition context.

Related Party Transactions

• scPharmaceuticals Inc. issued an unsecured promissory note to MannKind Corporation, which is the Parent company in the previously disclosed Agreement and Plan of Merger. This constitutes a related party transaction as MannKind is the prospective acquirer.

Stakeholder Impact

• **Shareholders:** The financing provides liquidity to scPharmaceuticals, supporting its operations during the merger process, which could help preserve the value of the company prior to acquisition. However, it also adds debt to the company's balance sheet.
• **Creditors:** The new unsecured debt ranks below existing secured creditors. Covenants in the note reference and build upon those in the Existing Perceptive Credit Agreement, indicating potential implications for existing debt holders.
• **Employees, Customers, and Suppliers:** The provision of working capital helps ensure the continuity of business operations, which is generally positive for these stakeholders by maintaining stability and reducing immediate operational risks.

Next Steps

• scPharmaceuticals Inc. will make interest payments on the promissory note, with the first payment due November 6, 2025.
• The company will continue to operate under the terms of the Merger Agreement with MannKind Corporation.
• The promissory note will mature upon the earliest of September 23, 2026, payment of the merger termination fee, or consummation of a superior proposal.

Key Dates

Recommendation

The filing details a bridge loan that is a procedural and expected step within the context of an already announced merger agreement. It provides necessary working capital for scPharmaceuticals Inc. during the acquisition process. This event does not fundamentally alter the investment thesis for scPharmaceuticals, which is primarily driven by the terms and likelihood of the merger's completion. Therefore, a "hold" recommendation is appropriate, as investors should await further developments regarding the merger itself.

Keywords

scPharmaceuticals, MannKind, Promissory Note, Debt Financing, Merger Agreement, Bridge Loan, Working Capital, SEC Filing, SCPH, Acquisition, Corporate Finance, Unsecured Debt